Relief of parkinsonism and dyskinesia: One and the same dopaminergic mechanism?

Neurology

Volumn 74, Issue 15, 2010, Pages 1169-1170

  Lewitt, Peter A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; LEVODOPA;

DISABILITY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DYSKINESIA; EDITORIAL; GENOTYPE; HUMAN; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR GENE; SYMPTOM;

EID: 77950931599     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d90076     Document Type: Editorial

References (11)

1. Nutt JG, Chung KA, Holford NHG. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010;74:1191-1197.
2. LeWitt PA, Ward CD, Calne DB. Spontaneous dyskinesia and dystonia at onset of levodopa use: control with bro-mocriptine. Arch Neurol 1988;45:207.
3. Parkinson Study Group. Impact of deprenyl and tocoph-erol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45.
4. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
5. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskine-sia Rating Scale: presentation and clinimetric profile. Mov Disord 2008;23:2398-2403.
6. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
7. Zappia M, Annesi G, Nociletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson's disease: an exploratory study. Arch Neurol 2005;62:601-605.
8. Lesage S, Belarbi S, Troiano A, et al. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? Neurology 2008;71:1550-1552.
9. Kaiser R, Hofer A, Grapengiesser A, et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003;60:1750-1755.
10. Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006;21:654-659.
11. Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:141-144.